Rational Pharmacotherapy in Cardiology

Advanced search

Chronic Heart Failure in Patients with Arterial Hypertension Associated with Obstructive Sleep Apnea Syndrome: Possible Options to Pathogenetic Therapy

Full Text:


Aim. To study approaches to the treatment of chronic heart failure (CHF) with reduced and mid-range left ventricular ejection fraction (LVEF) in patients with arterial hypertension (AH) against the background of obstructive sleep apnea (OSA).

Material and methods. The study included 136 patients with CHF and AH. Inclusion criteria for the study: 1) moderate and severe OSA (with an apnea/hypopnea index of more than 15 per hour); 2) II-IV functional class of CHF according to NYHA; 3) the level of brain natriuretic peptide precursor (NT-proBNP) ≥125 pg/ml; 3) LVEF <50%; 4) the duration of hypertension is at least 2 years. Patients received drug therapy, including beta-blockers, mineralocorticoid receptor antagonists, diuretics, ACE inhibitors or angiotensin receptor inhibitors or valsartan/sacubitrile. After 12 months of followup, the patients were divided into 2 groups depending on the medication being administered. Group 1 included patients (n = 50) receiving therapy with valsartan/sacubitril, group 2 included patients (n = 86) receiving therapy without this drug. Effective CPAP-therapy also was registered in each group.

Results. In patients with CHF who received valsartan/sacubitril, disease progression was recorded in 28% of cases, while in patients who did not receive therapy with this drug, an unfavorable course of CHF was recorded in 42.8% (p = 0.001). In group 1, the NT-proBNP level significantly (p = 0.034) decreased by 34%, while in group 2, a significant (p = 0.002) increase in biomarker levels was revealed by 35.5%. In the group of patients receiving therapy with valsartan/sacubitril an increase in LVEF (p = 0.007) was revealed by 12.5%. In group 1, an increase in exercise tolerance was achieved in the form of a significant (p = 0.012) increase in the distance of the six-minute walk test by 18.2%, while in group 2, the six-minute walk distance decreased by 19.2% (p = 0.034). In the subgroup of patients receiving CPAP therapy in combination with valsartan/sacubitril therapy (n=8), LVEF increased by 11.6% (p = 0.043), the six-minute walk test distance increased by 29.7% (p = 0.046), and NT-proBNP decreased by 22.5% (p = 0.039), while in the group of patients who received only CPAP therapy (n=19).

Conclusion. The most significant slowdown in the rate of progression of CHF in patients with AH associated with OSA, an increase in exercise tolerance, as well as the most pronounced tendency to the reverse development of pathological echocardiographic changes in the myocardium when using valsartan/sacubitrile in drug therapy in combination with effective hardware CPAP therapy.

About the Authors

A. V. Yakovlev
Novosibirsk State Medical University
Russian Federation

Alexey V. Yakovlev

S. N. Shilov
Novosibirsk State Medical University
Russian Federation

Sergey N. Shilov

E. N. Berezikova
Novosibirsk State Medical University
Russian Federation

Ekaterina N. Berezikova

N. F. Yakovleva
Novosibirsk State Medical University
Russian Federation

Natalia F. Yakovleva

A. T. Teplyakov
Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology Research Institute
Russian Federation

Aleksander T. Teplyakov

E. V. Grakova
Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology Research Institute
Russian Federation

Elena V. Grakova

K. V. Kopeva
Tomsk National Research Medical Center, Russian Academy of Sciences, Cardiology Research Institute
Russian Federation

Kristina V. Kopeva

I. A. Efremov
Novosibirsk State Medical University
Russian Federation

Ivan A. Efremov


1. van Deursen VM, Urso R, Laroche C, et al. Comorbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16:103-11. DOI:10.1002/ejhf.30.

2. Lindberg E, Gislason T. Epidemiology of sleep-related obstructive breathing. Sleep Med Rev. 2000;4:321-7. DOI:10.1053/smrv.2000.0118.

3. Mentz RJ, Fiuzat M. Sleep-Disordered Breathing in Patients with Heart Failure Heart Failure Clin. 2014;10:243-50. DOI:10.1016/j.hfc.2013.10.001.

4. Butt M, Dwivedi G, Khair O, et al. Obstructive sleep apnea and cardiovascular disease. Int J Cardiol. 2010;139:7-16. DOI:10.1016/j.ijcard.2009.05.021.

5. Marin JM, Agusti A, Villar I, et al. Association Between Treated and Untreated Obstructive Sleep Apnea and Risk of Hypertension. JAMA. 2012;307(20):2169-76. DOI:10.1001/jama.2012.3418.

6. Bitter T, Westerheide N, Prinz C, et al. Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J. 2011;32:61-74. DOI:10.1093/eurheartj/ehq327.

7. Nieto FJ, Young TB, Lind BК, et al. Association of sleep-disordered breathing, sleep apnea and hypertension in a large community-based study. JAMA. 2000;283(14):1829-36. DOI:10.1001/jama.283.14.1829.

8. Sauer AJ, Cole R, Jensen BC, et al. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2019;24(2):167-76. DOI:10.1007/s10741-018-9757-1.

9. Khder Y, Shi V, McMurray JJV, et al. Sacubitril/Valsartan (LCZ696) in Heart Failure. Handb Exp Pharmacol. 2017;243:133-65. DOI:10.1007/164_2016_77.

10. Denker MG, Cohen DL. Use of continuous positive airway pressure for sleep apnea in the treatment of hypertension. Curr Opin Nephrol Hypertens. 2014;23(5):462-67. DOI:10.1097/MNH.0000000000000047.

11. Mansukhani MP, Vungarala S, Somers VK. Cardiovascular Benefits of Continuous Positive Airway Pressure: The Quest Continues. Ann Am Thorac Soc. 2020;17(4):427-28. DOI:10.1513AnnalsATS.202001-026ED.

12. Carmo J, Araújo I, Marques F, et al. Sleep-disordered breathing in heart failure: The state of the art after the SERVE-HF trial. Rev Port Cardiol. 2017;36(11):859-67. DOI:10.1016/j.repc.2017.06.007.

13. Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158 (In Russ.) DOI:10.18087/cardio.2475.

14. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479-504. DOI:10.5664/jcsm.6506.

15. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-7. DOI:10.1164/ajrccm.166.1.at1102.

16. Javaheri S, Caref EB, Chen E, et al. Sleep apnea testing and outcomes in a large cohort of medicare beneficiaries with newly diagnosed heart failure. Am J Respir Crit Care Med. 2011;183:539-46. DOI:10.1164/rccm.201003-0406OC.

17. Liu Y, Huang Z, Huang K, et al. The Clinical Value of N-Terminal Pro B-Type Natriuretic Peptide in Evaluating Obstructive Sleep Apnea in Patients With Coronary Artery Disease. J Clin Sleep Med. 2019;15(10):1403-9. DOI:10.5664/jcsm.7962.

18. Hübner RH, Mokhtari NE, Freitag S, et al. NT-proBNP is not elevated in patients with obstructive sleep apnoea. Respir Med. 2008;102(1):134-42. DOI:10.1016/j.rmed.2007.07.023.

19. Kasai T, Bradley TD. Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. J Am Coll Cardiol. 2011;57(2):119-27. DOI:10.1016/j.jacc.2010.08.627.

20. Tugcu A, Guzel D, Yildirimturk O, et al. Evaluation of right ventricular systolic and diastolic function in patients with newly diagnosed obstructive sleep apnea syndrome without hypertension. Cardiology. 2009;113:184-92. DOI:10.1159/000193146.

21. Tasci S, Manka R, Scholtyssek S, et al. NT-pro-BNP in obstructive sleep apnea syndrome is decreased by nasal continuous positive airway pressure. Clin Res Cardiol. 2006;95(1):23-30. DOI:10.1007/s00392-006-0315-9.

22. Nakamura S, Asai K, Kubota Y, et al. Impact of sleep-disordered breathing and efficacy of positive airway pressure on mortality in patients with chronic heart failure and sleepdisordered breathing: a meta-analysis. Clin Res Cardiol. 2015;104:208-16. DOI:10.1007/s00392-014-0774-3.

23. Arias MA, García-Río F, Alonso-Fernández A, et al. Pulmonary hypertension in obstructive sleep apnoea: Effects of continuous positive airway pressure: A randomized, controlled cross-over study. Eur Heart J. 2006;27:1106-13. DOI:10.1093/eurheartj/ehi807.


For citations:

Yakovlev A.V., Shilov S.N., Berezikova E.N., Yakovleva N.F., Teplyakov A.T., Grakova E.V., Kopeva K.V., Efremov I.A. Chronic Heart Failure in Patients with Arterial Hypertension Associated with Obstructive Sleep Apnea Syndrome: Possible Options to Pathogenetic Therapy. Rational Pharmacotherapy in Cardiology. 2021;17(3):444-449. (In Russ.)

Views: 347

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)